Pharma: Getting Down to Business with Stem Cells

September 2009. Roger Perlmutter, CSO of Amgen, told the Financial Times about plans to enter into “business with stem cells”. Interestingly, his answers were not the usual honed and polished product of a corporate communications department, but delivered ‘straight from the hip’, so to speak, in direct response to the journalist’s questions. Editorial B2BioworldReading time: 6 minRead more ...

Other articles recommended

B2Bioworld offers you background information